Related Experiment Video
Updated: Aug 15, 2025

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
Published on: December 9, 2016
PAK1 and PAK4 as therapeutic targets for Ewing sarcoma: a commentary
Sydney E Parks1,2, Jason T Yustein1,2,3,4
1Texas Children's Cancer and Hematology Centers and The Faris D. Virani Ewing Sarcoma Center, Baylor College of Medicine, Houston, TX 77030, USA.
Abstract:
Ewing sarcoma (ES) is an aggressive pediatric bone tumor that is prone to metastasis. Due to low five-year survival rates and limited therapeutic options for metastatic disease, there is a dire clinical need for improved ES treatments. Targeting p21-activated kinases (PAKs) may be key. PAK1 and PAK4 are associated with aggressive ES and poor patient outcomes, although their molecular mechanisms remain largely uncharacterized in this disease. This commentary aims to highlight the recent advancements made to the understanding of PAK1 and PAK4 in ES in the paper "p21-activated kinases as viable therapeutic targets for the treatment of high-risk Ewing sarcoma" by Qasim et al.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
PI3K/mTOR/AKT Signaling Pathway

